Edgar Filing: Corvus Pharmaceuticals, Inc. - Form 4

Corvus Pharmaceuticals, Inc. Form 4							
March 24, 2016					OMB A	PPROVAL	
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940					3235-0287	
Section 16. Form 4 or Form 5 Filed purs						January 31 Expires: 2005 Estimated average burden hours per response 0.5	
(Print or Type Responses)							
1. Name and Address of Reporting I Verner Erik J.	Symbol	er Name and Ticker of Pharmaceuticals,	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (M CORVUS PHARMACEUTIC INC., 863 MITTEN ROAD, S 102	(Month/ CALS, 03/22/2	of Earliest Transaction Day/Year) 2016		Director X Officer (giv below) V.P., O			
(Street)		endment, Date Origina onth/Day/Year)	al	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person			
BURLINGAME, CA 94010				Form filed by Person	More than One R	eporting	
(City) (State)	(Zip) Tab	ole I - Non-Derivative	Securities A	cquired, Disposed o	of, or Beneficia	lly Owned	
(Instr. 3)		3. 4. Securit TransactionAcquired Code Disposed (Instr. 8) (Instr. 3,	(A) or of (D) 4 and 5) (A) or	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
Reminder: Report on a separate line	for each class of sec	Code V Amount urities beneficially ow		or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	5. Number of iorDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)8(Instr. 3 and 4)9		
				Code V	(A) (D)) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 15	03/22/2016		А	60,000	<u>(1)</u>	03/22/2026	Common Stock	60,000	
Reporting Owners										
Reporting Owner Name / Address					Relationships					
			Director 109	% Owner	Officer		Other			
Verner Erik J. CORVUS PHARMACEUTICALS, INC. 863 MITTEN ROAD, SUITE 102 BURLINGAME, CA 94010				V.P., Chemistry Research						
Signa	tures									
/s/ Leiv I Ph.D.	Lea, as Atto	rney-in-Fact for E	rik J. Verner,		03/24/2016					
		ture of Reporting Person			Date					
Explanation of Responses:										
* If the form is filed by more than one reporting person, <i>see</i> Instruction 4(b)(v).										

Edgar Filing: Corvus Pharmaceuticals, Inc. - Form 4

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The underlying shares subject to the option vest and become exercisable as to one-forty-eighth (1/48th) of the shares subject to the option (1) in successive, equal monthly installments measured from March 22, 2016, subject to Reporting Person's continued service relationship

with the Issuer on each such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.